This proof of principle study shows the potential of in situ sequencing revealing novel potential predictive biomarkers in colon cancer stage II, namely MMP11, FGFR2 and OTOP2, relevant for relapse of disease. This evidence concerns the gene OTOP2 and malignant colon neoplasm.